What did @catreaamcknight actually say?
Honestly, not much, at least not medically. The transcript is almost entirely emotional: "it's lowkey scary watching you from before getting fine and healing from everything you done been through." That's it. There's no claim about how GLP-1 medications work, no dosing advice, no before-and-after explanation. The actual pitch lives in the caption, which promotes a $40 discount on Mochi Health's first-month membership fee via an affiliate link. The hashtags do the heavy lifting: #pcos, #glp1, #beforeandafter, #bodytransformation. The video is a sponsored weight-loss transformation post. That's the honest description.
The creator is transparent about the partnership using #mochipartner, which is the right move under FTC guidelines. But the combination of PCOS and GLP-1 hashtags alongside vague "healing" language implies a therapeutic narrative that the transcript never actually supports with facts.
Does the science back up the implied PCOS and GLP-1 connection?
There's real evidence here, but it's more complicated than a transformation video suggests. GLP-1 receptor agonists like semaglutide and tirzepatide have shown meaningful benefit for people with PCOS, primarily through weight loss and improved insulin sensitivity. The implied connection is not fabricated.
A 2023 randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (Jensterle et al.) found semaglutide significantly reduced body weight and improved hormonal markers in women with PCOS compared to placebo. Tirzepatide, which targets both GLP-1 and GIP receptors, showed even broader metabolic improvements in the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), though that trial was not PCOS-specific. The weight loss component alone can restore ovulatory function in some patients, according to a review by Lim et al. (2019, Human Reproduction Update).
So the hashtag pairing of #pcos and #glp1 isn't wrong. It's just presented without any of that context, which leaves viewers to fill in the blanks with their own assumptions.
What did they get wrong, or right?
The creator didn't get the science wrong because they didn't state any science. That's both the defense and the problem. By anchoring the post emotionally around "healing" and pairing it with PCOS and GLP-1 hashtags, the video implies a cause-and-effect story it never earns.
What they got right: disclosure. The #mochipartner tag is present, the discount is clearly stated in the caption, and there's no false medical claim in the spoken transcript. That's a low bar, but it's cleared.
What's missing: any acknowledgment that GLP-1 medications require a clinical evaluation, carry real side effects including nausea, vomiting, and pancreatitis risk, and are not universally appropriate for people with PCOS. The FDA has not approved semaglutide or tirzepatide specifically for PCOS treatment. Using them off-label for that indication is a prescriber's decision, not a TikTok affiliate link decision. Viewers who click that link expecting a PCOS cure are going to find a telehealth intake form, which may or may not result in a prescription. That gap matters.
What should you actually know before clicking that link?
Mochi Health is a legitimate telehealth platform that prescribes GLP-1 medications. A membership fee is not a prescription guarantee. You will still go through a clinical screening process, and not everyone will qualify. The $40 discount is on the membership fee, not the medication itself, and GLP-1 drugs remain expensive without adequate insurance coverage.
If you have PCOS and are considering a GLP-1 medication, the conversation should start with your gynecologist or endocrinologist, not a TikTok affiliate link. That said, telehealth platforms can be a legitimate access point for people without specialist coverage. Just know what you're signing up for.
- GLP-1 medications can cause significant gastrointestinal side effects, especially in the early titration phase.
- Compounded semaglutide is not the same as FDA-approved Wegovy or Ozempic. Formulations differ and are not interchangeable.
- Weight loss from GLP-1 drugs is typically not permanent without continued use. The STEP 4 trial (Rubino et al., 2021, JAMA) showed significant weight regain after discontinuation.
- For PCOS specifically, the evidence on GLP-1 medications is promising but still emerging. Most trials are small and short-term.